Medifocus Announces Extension of Warrants Expiry Date

TORONTO, ONTARIO--(Marketwire - April 25, 2012) - Medifocus Inc. (Medifocus or the Company) (TSX VENTURE:MFS)(OTCQX:MDFZF) is pleased to announce that it has received approval from the TSX Venture Exchange (the Exchange) to extend until April 24, 2013 the expiry date of 2,449,997 outstanding common share purchase warrants (the Warrants) issued pursuant to the private placement announced on April 9, 2010. Each Warrant entitles the holder to acquire one common share of Medifocus at a price of $0.50. In accordance with Exchange Policy 4.1, the Warrants will be amended to reduce the exercise period to 30 days if, for any ten consecutive trading days during the unexpired term of the Warrants, the closing price of the Company's common shares on the Exchange exceeds $0.62. Such acceleration price was previously $0.75.

All other terms and conditions of the Warrants will remain unchanged and in full force and effect.

About Medifocus Inc.

Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array (APA) technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumours with a precision controlled dose of heat can be used to destroy tumours at higher temperatures, to treat tumours in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumour sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. Please visit www.medifocusinc.com for more details.